华兰生物
(002007)
| 流通市值：267.92亿 | | | 总市值：311.26亿 |
| 流通股本：15.74亿 | | | 总股本：18.29亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,490,648,261.92 | 1,652,707,481.28 | 787,309,418.97 | 5,341,872,557.46 |
| 营业收入 | 3,490,648,261.92 | 1,652,707,481.28 | 787,309,418.97 | 5,341,872,557.46 |
| 二、营业总成本 | 2,431,324,369.49 | 1,256,230,119.09 | 544,582,536.78 | 3,424,990,839.29 |
| 营业成本 | 1,334,425,541.24 | 814,929,187.59 | 348,950,838.18 | 1,624,478,237.52 |
| 税金及附加 | 28,469,899.53 | 17,388,160.46 | 8,366,164.78 | 44,623,343.92 |
| 销售费用 | 615,728,437.86 | 122,308,324.35 | 44,727,602.74 | 1,202,428,525.24 |
| 管理费用 | 249,830,845.9 | 165,209,089.59 | 72,757,439.48 | 274,288,489.62 |
| 研发费用 | 211,913,321.3 | 144,659,398.85 | 72,713,577.15 | 280,843,979.31 |
| 财务费用 | -9,043,676.34 | -8,264,041.75 | -2,933,085.55 | -1,671,736.32 |
| 其中:利息费用 | 11,378,340.78 | 8,208,245.71 | 4,503,333.34 | 13,172,369.79 |
| 其中:利息收入 | 20,817,849.92 | 16,747,510.16 | 7,670,193.22 | 15,425,637.26 |
| 加:公允价值变动收益 | 23,628,242.37 | 19,356,426.44 | 9,462,052.83 | 60,544,227.95 |
| 加:投资收益 | 103,562,812.67 | 67,879,421.27 | 34,260,128.01 | 149,045,587.36 |
| 资产处置收益 | 54,118.05 | 122,811.82 | 74,937.31 | 44,443,673.01 |
| 资产减值损失(新) | - | - | - | -90,878,652.81 |
| 信用减值损失(新) | 7,303,657.36 | 41,936,021.04 | 33,924,838.11 | -13,923,571.52 |
| 其他收益 | 28,025,139.33 | 13,185,880.95 | 10,681,292.63 | 32,277,222.01 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,221,897,862.21 | 538,957,923.71 | 331,130,131.08 | 2,098,390,204.17 |
| 加:营业外收入 | 3,283,673.68 | 3,251,422.48 | 240,241.27 | 257,306.51 |
| 减:营业外支出 | 26,420,816.26 | 8,291,892.69 | 2,995,280.4 | 21,004,842.29 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,198,760,719.63 | 533,917,453.5 | 328,375,091.95 | 2,077,642,668.39 |
| 减:所得税费用 | 187,601,764.85 | 85,142,182.97 | 54,003,227.96 | 315,957,773.72 |
| 六、净利润 | 1,011,158,954.78 | 448,775,270.53 | 274,371,863.99 | 1,761,684,894.67 |
| 持续经营净利润 | 1,011,259,458.85 | 448,875,774.6 | 274,371,863.99 | 1,761,684,894.67 |
| 终止经营净利润 | -100,504.07 | -100,504.07 | - | - |
| 归属于母公司股东的净利润 | 923,656,831.05 | 440,196,094.59 | 261,773,937.6 | 1,481,578,849.25 |
| 少数股东损益 | 87,502,123.73 | 8,579,175.94 | 12,597,926.39 | 280,106,045.42 |
| (一)基本每股收益 | 0.51 | 0.24 | 0.14 | 0.81 |
| (二)稀释每股收益 | 0.5 | 0.24 | 0.14 | 0.81 |
| 九、综合收益总额 | 1,011,158,954.78 | 448,775,270.53 | 274,371,863.99 | 1,761,684,894.67 |
| 归属于母公司股东的综合收益总额 | 923,656,831.05 | 440,196,094.59 | 261,773,937.6 | 1,481,578,849.25 |
| 归属于少数股东的综合收益总额 | 87,502,123.73 | 8,579,175.94 | 12,597,926.39 | 280,106,045.42 |
| 公告日期 | 2024-10-30 | 2024-08-30 | 2024-04-26 | 2024-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |